Talking Precision Medicine
Najat Khan | Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM #44
Mar 28, 2025
Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharmaceuticals, dives into the revolutionary impact of AI on drug discovery. She shares insights on how tech-driven biotech firms are transforming the pharmaceutical landscape. The discussion highlights the vital role of AI in clinical development and data integration for better patient outcomes. Exploring challenges and innovations, Najat emphasizes the need for a skilled workforce that bridges science and technology, paving the way for future biotech advancements.
38:35
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Recursion Pharmaceuticals leverages an integrated AI tech stack to streamline drug development, enhancing precision medicine through targeted therapies and patient identification.
- The company's culture fosters collaboration across scientific and commercial domains, enabling innovative approaches to complex challenges in drug development and clinical trial outcomes.
Deep dives
AI-Driven Drug Development
Recursion Pharma utilizes an integrated AI tech stack to enhance the entire drug development process, from discovery to clinical trials. By generating proprietary, high-quality data, Recursion can leverage machine learning to gain insights into biological mechanisms driving diseases. This data supports the design of targeted molecules and aids in identifying suitable patients for clinical trials, fulfilling the long-sought goal of precision medicine. The company has successfully established a diverse pipeline with over 30 projects across various therapeutic areas including oncology, immunology, and rare diseases.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
